Application of this bioinformatic strategy selected four factors for further analysis: NOVA1, PRPF8, SRSF1 and SRSF9, while clinical association with tumor size suggested an additional candidate, SRSF10. The inclusion of SRSF10 in the study was also motivated by its well described pro-malignant role in other tumors [49, 50]. This evidence concerns the gene SRSF9 and neoplasm.